This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXMPEIAF0J7_L.jpg
The company is seeking to raise money from the possible sale of the assets to invest in cutting-edge medicines, the report said, adding that the ophthalmology unit could alone fetch about $5 billion.
The drugmaker did not immediately respond to a Reuters request for comment.
In August, Novartis said it was planning to spin off its generics unit, Sandoz, to sharpen its focus on its patented prescription medicines.
(This story has been refiled to correct typo in headline, paragraph 1)
